Back to top

Analyst Reiterates Buy on IKT, Maintaining $8 Price Target Amid Regulatory Progress and Phase 3 PAH Trial Momentum

Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Inhibikase Therapeutics and keeping the price target at $8.00. Ram Selvaraju ...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Inhibikase Therapeutics, Inc. (IKT)